Acrobiosystems for English
icon_bulk_orderBulk inquiry/Quick order
There is no goods in the shopping cart !
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 0-9
Your Position: Home > Licensing > BLL202201

TIM3×PD-1 bsAb

BLA Filing
  • Project profile
    Project name: TIM3×PD-1 bsAb
    Indications: Solid Tumor
    Research phase: Phase 1
    Cooperation demands: License-out or co-development
  • Highlights

    1. Clear MoA.

    TIM3×PD-1 bsAb

    1)TIM3 is an inhibitory immune checkpoint that is expressed on the surface of T cells, DCs, Treg cells and other innate immune cells, and can cause T cell exhaustion and tumor immune escape.

    2)Patients with TIM3 overexpressing show ineffective anti-PD1 therapy.

    3)Dual-blockade of TIM3 and PD1 can significantly activate antitumor effects.

    2. TIM3 × PD1 bsAb is the first to simultaneously release the inhibitory activity of DCs, T cells, and NK cells.

    1) Significantly activate the tumor-killing activity of NK cells

    2) Restore DCs antigen-presenting ability and T cells tumor-killing activity

    3. high binding affinity.

    1) Anti-PD-1 effect in liver cancer is comparable to Keytruda(77-88%TGI);

    2) Anti-TIM3 ability is stonger than RG7769;

    3) Anti-TIM3 ability of the BsAb is comparable to anti-PD-1(approximated 5-8nM).

    4. BsAb shows high antitumor activity in PD1 insensitive mouse model and at the day 40 the survival ratio reachs to 85% which is superior to a combination of anti-TIM3 and anti-PD1 due to synergistic effects.

    5. Good PK/PD property.

    1) HNSTD=200 mpk;

    2) At the dose of 2、10、50 mpk,ADA=33.3%(2/6)、83.3%(5/6)and 0.0%(0/6);

    3) At the dose of 2-50 mpk,t1/2=31.7-66.5 h.

  • Project Introduction

    1. Asset type: TIM3×PD-1 bsAb

    2. Indication: Solid Tumor

    4. Research phase: Phase 1

    5. Cooperation demands:   License-out or co-development

    6. Research progress:

    1) Got document for clinical trials in China and USA, Phase Ⅰ in China and have plans of second or third treatment for NSCLC(10 patients).

    2) The pre-clinical data is more competitive than other products in clinical.

    3) Inhibit tumor growth in PD-1 insensitive model, prolong survival ratio and its effectiveness is better than solitary drug or combination.

    4) Good safety and PK/PD property.

Comments (0)

New Product Launch

Questions & Comments

This web search service is supported by Google Inc.

Call us
Call us
North America:
+1 800-810-0816 (Toll Free)
Asia & Pacific:
+86 400-682-2521
+1 888-377-6111
1 Innovation Way, Newark, DE 19711, USA

Leave a message